Synthetic scaffold

Biodegradable, Synthetic Meniscus Scaffold

Orteq has developed ACTIfit in conjunction with the world’s leading joint preservation surgeons. With over 4,000 treated patients and over 25 peer-reviewed publications cited in over 100 peer reviewed publications, ACTIfit is available in more than 30 countries worldwide.

Made from our proprietary polymer, ACTIfit is the first biodegradable, synthetic scaffold, designed to help restore meniscal tissue loss. ACTIfit is safe, tough, and easy to handle in surgery and is currently being evaluated in other unmet clinical needs across a number of joints in the body.

ACTIfit meniscal scaffold granted US FDA Breakthrough Designation.

Why Save the Meniscus?

Orteq targeted knee injuries first with ACTIfit because there is no option to regenerate a patient’s meniscus once the damaged section of the meniscus has been removed via a partial meniscectomy. Every year there are more than 1,500,000 meniscectomies and 630,000 total knee replacements performed in the US and Europe. ACTIfit has significant potential to improve joint health and delay the need for joint replacement.

ACTIfit helps facilitate the human body’s natural healing process by providing a scaffold to fill the injured area and allow blood flow and cells to stimulate new tissue growth.

This polymer platform of the biodegradable scaffold that helps promote new tissue in-growth is currently being adapted for use in to preserve other joints in the body.

Clinical Results

ACTIfit’s five-year clinical results have recently been published in the American Journal of Sports Medicine, published in over 25 peer-reviewed clinical papers, and cited in over 100 journal articles. Key clinicians from across the world have presented ACTIfit in congresses and conferences over the last 10 years.

Polyurethane Meniscal Scaffold for the Treatment of Partial Meniscal Deficiency: 5 Year Follow-up Outcomes
A European Multicentric Study

Cecile Toanen, MD, Aad Dhollander, MD, PT, PhD, Paolo Bulgheroni, MD, Giuseppe Filardo, MD, PhD, Stefano Zaffagnini, MD, PhD, Tim Spalding, MD, Joan Carles Monllau, MD, PhD, Pablo Gelber, MD, Rene Verdonk, MD, PhD, Philippe Beaufils, MD, PhD, Nicolas Pujol, MD, PhD, and Peter Verdonk, Md, PhD.

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Click here to see the AJSM publication of ACTIfit's 5-year results

What is ACTIfit?

ACTIfit is a synthetic implantable scaffold with a highly interconnected pore structure.

  • Proprietary biocompatible and biodegradable polymer
  • Implanted arthroscopically into the knee of a patient’s irreparable meniscus
  • Promotes meniscus restoration from native tissue
  • Designed to support shock absorption of the native meniscus and promote pain relief and functional mobility
  • Intended for partial meniscus loss or damage
Close-up of ACTIfit’s honeycomb structure.
ACTIfit Medial and Lateral scaffolds.

The combination of the polymer’s honeycomb structural design and polymer strength and design promotes the in-growth of new tissue and results in a newly vascularised and functional meniscus.

Photo courtesy of Prof J Bellemans, UZ, Leuven, Belgium.

The knee joint is one of the most biomechanically severe environments in the human body, a successful orthopedic meniscal implant should satisfy two fundamental criteria:

  • be strong enough to retain the sutures prior to integration with native meniscus tissue, and
  • have an open and interconnected pore structure into which blood vessels can grow, allowing the generation of new cartilage cells and tissue.

The ACTIfit polymer and scaffold were specifically designed to meet these demanding requirements.



Clinical Studies






Patients Treated


FDA Breakthrough Designation